Micke et al. 19 examined the influence of CD117 on survival in extended-stage small-cell lung cancer, and found that patients with CD117 expression and a minor response to chemotherapy had shorter survival times than those with CD117-negative tumours. This evidence concerns the gene KIT and neoplasm.